Journal of Clinical Oncology, Vol 7, 706-709, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

BL Hillcoat, D Raghavan, J Matthews, R Kefford, K Yuen, R Woods, I Olver, J Bishop, B Pearson and G Coorey
Department of Cancer Medicine, Peter MacCallum Cancer Institute, Melbourne, Australia.

One hundred eight patients with recurrent or metastatic transitional cell carcinoma of the urothelial tract were randomized to receive cisplatin (C) 80 mg/m2 on day 1 every 4 weeks, or methotrexate (M) 50 mg/m2 on days 1 and 15 plus C 80 mg/m2 on day 2 every 4 weeks (C + M). Fifty-three eligible patients were randomized to C + M and 55 to C. In the C + M arm, 45% of patients responded (complete response [CR], 9%) and 31% (CR, 9%) in the C arm (P = .18). In the C arm, 20 patients failing or relapsing after C received M. Two patients responded, and four with progressive disease (PD) and one with a previous partial response (PR) showed no change. The median survival was 8.7 months (C + M arm) and 7.2 months (C arm), P = .7. Relapse-free survival was not significantly different, but C + M was associated with a significantly increased time to disease progression (median, 5.0 months, v 2.8 months for C arm). The response of untreated patients (37%) was not different from those with prior treatment (39%). On the C + M arm, 92% of patients and 96% of patients on the C arm received 85% or more of the scheduled C dose. Significantly more grade 3 or 4 hematological toxicity (27% v 2%; P = .01) and mucositis (20% v 0%; P = .0005) occurred in patients on the C + M arm. Although the initial response rates seen on the combination arm look superior, and the time to disease progression is increased, these effects have not translated into a clinically important increase in the duration of survival and were associated with increased toxicity.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. D. Galsky and H. I. Scher Bladder Cancer "Adjuvant-Lite": Tastes Great (works as well) and Less Filling (less toxic)? J. Clin. Oncol., August 1, 2005; 23(22): 4823 - 4826. [Full Text] [PDF]

				J. Lehmann, M. Retz, C. Wiemers, J. Beck, J. Thuroff, C. Weining, P. Albers, D. Frohneberg, T. Becker, P.-J. Funke, et al. Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95) J. Clin. Oncol., August 1, 2005; 23(22): 4963 - 4974. [Abstract] [Full Text] [PDF]